Founded in 2005 in Cambridge UK, Sentinel Oncology is dedicated to the development and commercialization of new therapeutics Our core strength is the development of highly selective and targeted oncology candidate drugs. Our pipeline strategy is focused on the design and optimisation of new drugs which can be used to treat primary brain tumours or systemic tumours which frequently spread to the brain.